dc.relation.reference | 1. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26(1):43-9.
2. McDonald LC, Lauderdale TL, Shiau YR, et al. The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000. Int J Antimicrob Agents 2004;23(4):362-70.
3. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17(3):479-501.
4. Spencer RC, Goering R. A critical review of the in-vitro activity of teicoplanin. Int J Antimicrob Agents 1995;5:169-77.
5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36(1):53-9.
6. Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000;45(6):835-41.
7. Wilson AP, Gruneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993;32(6):792-6.
8. Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC. Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J Antimicrob Chemother 2002;49(2):423-4.
9. Hassan IA, Chadwick PR, Johnson AP. Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin in Northwest England. J Antimicrob Chemother 2001;48(3):454-5.
10. Watanakunakorn C. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. J Antimicrob Chemother 1988;22(3):321-4.
11. Watanakunakorn C. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin. J Antimicrob Chemother 1990;25(1):69-72.
12. Thompson GA, Smithers JA, Kenny MT, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers. Biopharm Drug Dispos 1992;13(3):213-20.
13. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39(3):167-83.
14. Rowland M. Clinical pharmacokinetics of teicoplanin. Clinical pharmacokinetics 1990;18(3):184-209.
15. Sato M, Chida K, Suda T, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother 2006;12(4):185-9.
16. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother 1991;35(1):79-87.
17. Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996;40(5):1242-7.
18. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003;51(4):971-5.
19. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36(11):1418-23.
20. Fitch L, Johnson AP. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 1998;41(5):578.
21. Parenti F, Beretta G, Berti M, Arioli V. Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. J Antibiot (Tokyo) 1978;31(4):276-83.
22. Borghi A, Coronelli C, Faniuolo L, Allievi G, Pallanza R, Gallo GG. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin). J Antibiot (Tokyo) 1984;37(6):615-20.
23. Malabarba A, Strazzolini P, Depaoli A, Landi M, Berti M, Cavalleri B. Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products. J Antibiot (Tokyo) 1984;37(9):988-99.
24. Parenti F, Schito GC, Courvalin P. Teicoplanin Chemistry and Microbiology. J Chemother 2000;12 Suppl 5:5-14.
25. Wilson APR, Grüneberg RN. Teicoplanin: the first decade. Oxford: The Medicine Group; 1997.
26. Campoli-Richard DM, Brogden RN, Faulds D. Teicoplanin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990;40(3):449-86.
27. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989;8(11):943-50.
28. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990;34(4):510-4.
29. Neu HC, Labthavikul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 1983;24(3):425-8.
30. Wilson AP, O'Hare MD, Felmingham D, Gruneberg RN. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 1986;2(8513):973.
31. Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990;40(3):449-86.
32. Rybak MJ, Bailey EM, Reddy VN. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob Agents Chemother 1991;35(8):1586-90.
33. Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother 1990;34(11):2114-7.
34. Smithers JA, Kulmala HK, Thompson GA, et al. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers. Antimicrob Agents Chemother 1992;36(1):115-20.
35. Carver PL, Nightingale CH, Quintiliani R, Sweeney K, Stevens RC, Maderazo E. Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob Agents Chemother 1989;33(1):82-6.
36. Lam YW, Kapusnik-Uner JE, Sachdeva M, Hackbarth C, Gambertoglio JG, Sande MA. The pharmacokinetics of teicoplanin in varying degrees of renal function. Clin Pharmacol Ther 1990;47(5):655-61.
37. Antony KK, Lewis EW, Kenny MT, et al. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci 1991;80(6):605-7.
38. Del Favero A, Patoia L, Rosina R, et al. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother 1991;35(12):2551-7.
39. Danese A, Bernareggi A, Rosina R, Rowland M. Model choice for teicoplanin kinetics in man. Eur J Drug Metab Pharmacokinet 1991;Spec No 3:250-5.
40. Smithers JA, Thompson GA, Kenny MT, et al. Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1. Biopharm Drug Dispos 1992;13(8):571-81.
41. Bernareggi A, Danese A, Cometti A, Buniva G, Rowland M. Pharmacokinetics of individual components of teicoplanin in man. J Pharmacokinet Biopharm 1990;18(6):525-43.
42. Ripa S, Ferrante L, Mignini F, Falcioni E. Pharmacokinetics of teicoplanin. Chemotherapy 1988;34(3):178-84.
43. Assandri A, Bernareggi A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol 1987;33(2):191-5.
44. Bernareggi A, Borgonovi M, Del Favero A, Rosina R, Gavanaghi L. Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers. Eur J Drug Metab Pharmacokinet 1991;Spec No 3:256-60.
45. Buniva G, Del Favero A, Bernareggi A, Patoia L, Palumbo R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 1988;21 Suppl A:23-8.
46. Stahl JP, Croize J, Wolff M, et al. Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis. J Antimicrob Chemother 1987;20(1):141-2.
47. Exner K, Lang E, Borsche A, Lemperle G. Efficacy, tolerability and pharmacokinetics of teicoplanin in patients undergoing breast surgery. Eur J Surg 1992(Suppl. 567):33-8.
48. Lenders H, Walliser D, Schumann K. Teicoplanin-spiegel in tonsillen-schleimhaut-, knorpel und Knochengewebe. Fortschr antimicrob Antineoplast chemother 1991;10-2:119-21.
49. Holzapfel L, Ract C, Jeannot T, et al. Penetration of teicoplanin into the sinuses of patients with nosocomial sinusitis [abstract]. In: 14th Interdisciplinary meeting on anti-infectious chemotherapy; 1994 Dec 1-2; Paris; 1994. p. 243.
50. Nehrer S, Thalhammer F, Schwameis E, Breyer S, Kotz R. Teicoplanin in the prevention of infection in total hip replacement. Arch Orthop Trauma Surg 1998;118(1-2):32-6.
51. de Lalla F, Novelli A, Pellizzer G, et al. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993;37(12):2693-8.
52. Miglioli PA, Merlo F, Fabbri A, Padrini R. Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery. J Antimicrob Chemother 1997;39(2):229-33.
53. Martin C, Bourget P, Alaya M, et al. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997;41(5):1150-5.
54. Frank UK, Schmidt-Eisenlohr E, Mlangeni D, et al. Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery. Antimicrob Agents Chemother 1997;41(11):2559-61.
55. Cruciani M, Navarra A, Di Perri G, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992;15(2):285-9.
56. Briggs MC, McDonald P, Bourke R, Smith G, McGalliard JN, Wong D. Intravitreal penetration of teicoplanin. Eye 1998;12 ( Pt 2):252-5.
57. De Lalla F, Alegente G, Zaffaina A. Penetration of teicoplanin into aqueous humor. In: 18th International Congress of chemotherapy; 1993.
58. Antoniadou A, Vougioukas N, Kavouklis E. Penetration of teicoplanin into human aqueous humor after subconjunctival and IV administration [abstract 248]. Clin Infect Dis 1998;27:967.
59. Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996;37(3):545-53.
60. Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans. Antimicrob Agents Chemother 1992;36(8):1744-9.
61. Papaioannou MG, Marinaki S, Pappas M, et al. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. Int J Antimicrob Agents 2002;19(3):233-6.
62. Mercatello A, Jaber K, Hillaire-Buys D, Coronel B, Berland J, Despaux E. Concentration of teicoplanin in the serum of adults with end stage chronic renal failure undergoing treatment for infection. J Antimicrob Chemother 1996;37(5):1017-21.
63. Wolter K, Claus M, Fritschka E. Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD). Eur J Clin Pharmacol 1994;46(2):179-80.
64. Hillaire-Buys D, Peyriere H, Lobjoie E, Bres J, Ossart M, Despaux E. Influence of arterio-venous haemofiltration on teicoplanin elimination. Br J Clin Pharmacol 1995;40(1):95-7.
65. Menth M, Fiegel P. Elimination of teicoplanin via different dialysis membranes: in-vitro investigation. Int J Antimicrob Agents 1992;1 Suppl A:45-8.
66. Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991;35(4):696-700.
67. Steer JA, Papini RP, Wilson AP, McGrouther DA, Parkhouse N. Teicoplanin versus flucloxacillin in the treatment of infection following burns. J Antimicrob Chemother 1997;39(3):383-92.
68. Falcoz C, Ferry N, Pozet N, Cuisinaud G, Zech PY, Sassard J. Pharmacokinetics of teicoplanin in renal failure. Antimicrob Agents Chemother 1987;31(8):1255-62.
69. Bonati M, Traina GL, Villa G, et al. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet 1987;12(4):292-301.
70. Domart Y, Pierre C, Clair B, Garaud JJ, Regnier B, Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother 1987;31(10):1600-4.
71. Contrepois A, Joly V, Abel L, Pangon B, Vallois JM, Carbon C. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model. J Antimicrob Chemother 1988;21(5):621-31.
72. MacGowan A, White L, Reeves D, Harding I. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J infect Chemother 1996;2:197-208.
73. Guglielmo BJ. Principles of infectious diseases. In: Kacher BS, Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:56-23.
74. Van der Auwera P, Joly P. Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus. J Antimicrob Chemother 1987;19(3):313-20.
75. Van der Auwera P, Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously. J Antimicrob Chemother 1987;19(5):623-35.
76. Drabu YJ, Blakemore PH. The post-antibiotic effect of teicoplanin: monotherapy and combination studies. J Antimicrob Chemother 1991;27 Suppl B:1-7.
77. Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989;33(8):1193-7.
78. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother 1988;21 Suppl A:81-7.
79. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991;35(3):451-7.
80. Greenberg RN. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990;34(12):2392-7.
81. Martino P, Venditti M, Micozzi A, et al. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother 1989;33(8):1329-34.
82. Weinbren M, Struthers K. Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy. J Antimicrob Chemother 2002;50(2):306-7.
83. Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother 1988;21 Suppl A:61-7.
84. Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991;27 Suppl B:69-73.
85. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37(2):209-22.
86. Wilson ARP, Guneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994;4 (supple):1-30.
87. Frye RF, Job ML, Dretler RH, Rosenbaum BJ. Teicoplanin nephrotoxicity: first case report. Pharmacotherapy 1992;12(3):240-2.
88. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998;10(2):143-52.
89. Veldman RG, van der Pijl JW, Claas FH. Teicoplanin-induced thrombocytopenia. Nephron 1996;73(4):721-2.
90. Terol MJ, Sierra J, Gatell JM, Rozman C. Thrombocytopenia due to use of teicoplanin. Clin Infect Dis 1993;17(5):927.
91. Del Favero A, Patoia L, Bucaneve G, Biscarini L, Menichetti F. Leukopenia with neutropenia associated with teicoplanin therapy. Dicp 1989;23(1):45-7.
92. Agnelli G, Longetti M, Guerciolini R, et al. Effects of the new glycopeptide antibiotic teicoplanin on platelet function and blood coagulation. Antimicrobial agents and chemotherapy 1987;31(10):1609-12.
93. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
94. Huang PC, You SL, Lin YM, Chu CL. Body weight of Chinese adults by sex, age and body height and criterion of obesity based on body mass index. J Chinese Nutri Soc 1992;17:157-72.
95. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098.
96. Brater DC. Drug use in renal disease. In. Balgowlah: ADIS Health Science Press; 1983:29.
97. Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet 2004;43(6):405-15.
98. Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006;32(5):775-9.
99. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005;55(3):333-40.
100. Rouveix B, Jehl F, Drugeon H, Brumpt I, Caulin E. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults. Antimicrob Agents Chemother 2004;48(7):2394-9.
101. Pea F, Brollo L, Lugano M, Dal Pos L, Furlanut M. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001;23(5):587-8. | en |